The National Viral Hepatitis Control Programme (NVHCP) has completed eight years since its nationwide rollout, representing a significant milestone in India's public health initiatives. Launched to combat the silent epidemic of viral hepatitis, the programme has played a crucial role in reducing the disease burden across the country.
Understanding Viral Hepatitis
Viral hepatitis refers to inflammation of the liver caused by viral infections, primarily hepatitis A, B, C, D, and E. Among these, hepatitis B and C are particularly concerning as they can lead to chronic liver disease, cirrhosis, and liver cancer if left untreated. The World Health Organization estimates that viral hepatitis affects millions of Indians, though many remain undiagnosed due to the disease's asymptomatic nature in early stages.
The hepatitis B virus spreads through contact with infected blood or body fluids, while hepatitis C primarily transmits through blood-to-blood contact. Both viruses can silently damage the liver over decades, making early detection and treatment critical.
Programme Objectives and Reach
The NVHCP was designed with several key objectives to address India's hepatitis challenge:
- Provide free screening facilities at designated health centres across the country
- Ensure free diagnosis through laboratory testing for confirmed cases
- Offer free treatment with antiviral medications to eligible patients
- Create awareness about prevention, transmission, and available treatment options
- Strengthen laboratory networks for accurate diagnosis
- Train healthcare workers in hepatitis management
The programme operates through a network of government hospitals, community health centres, and district hospitals, making services accessible to populations in both urban and rural areas. This decentralised approach has been instrumental in reaching underserved communities.
Treatment Innovations
One of the programme's significant achievements has been making Direct-Acting Antivirals (DAAs) available for hepatitis C treatment. These modern medications can cure hepatitis C in 12 to 24 weeks with minimal side effects, representing a dramatic improvement over older interferon-based treatments that required longer duration and caused significant adverse effects.
For hepatitis B, the programme provides tenofovir-based antiviral therapy, which effectively suppresses viral replication and prevents disease progression. While hepatitis B cannot be completely cured, long-term antiviral therapy can prevent complications and improve quality of life.
Prevention Strategies
Beyond treatment, the NVHCP emphasises prevention through multiple channels:
- Universal immunisation against hepatitis B, included in India's routine childhood vaccination schedule
- Safe blood transfusion practices with mandatory screening
- Promotion of safe injection practices in healthcare settings
- Prevention of mother-to-child transmission through antenatal screening
- Awareness campaigns about safe practices and risk factors
The hepatitis B vaccine, provided free under the Universal Immunisation Programme, has been particularly effective in reducing new infections among children.
Challenges and Progress
Despite significant progress, challenges remain in achieving the WHO's goal of eliminating viral hepatitis as a public health threat by 2030. Major obstacles include:
- Low awareness leading to delayed diagnosis
- Stigma associated with the disease
- Gaps in screening coverage, particularly in remote areas
- Need for enhanced laboratory infrastructure
- Requirement for sustained political and financial commitment
However, the programme has made measurable progress in screening millions of individuals and initiating treatment for lakhs of patients with chronic hepatitis B and C. The integration of hepatitis services into existing health programmes has improved efficiency and reach.
What Individuals Can Do
Citizens can protect themselves and contribute to hepatitis elimination by:
- Getting vaccinated against hepatitis B
- Undergoing screening if at risk or never tested before
- Practising safe injection and blood transfusion practices
- Avoiding sharing of personal items like razors or toothbrushes
- Seeking immediate medical attention if diagnosed, as early treatment prevents complications
The Path Forward
As the NVHCP enters its ninth year, the focus remains on expanding coverage, improving diagnostic facilities, and ensuring treatment adherence. The programme's success depends on continued government commitment, public awareness, and community participation in screening drives.
The eight-year milestone represents not just longevity but evolution in India's approach to a preventable and treatable disease that affects millions. With sustained efforts, India can move closer to the WHO's elimination targets while improving liver health outcomes nationwide.
This article is for general informational purposes only and does not constitute medical advice. Individuals concerned about viral hepatitis should consult qualified healthcare professionals for personalised assessment and treatment recommendations.
